{"protocolSection": {"identificationModule": {"nctId": "NCT00698646", "orgStudyIdInfo": {"id": "CVAH631BUS08"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.", "officialTitle": "A 16 Week Multi-center, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide (HCTZ) Monotherapy in Very Elderly Patients With Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-04"}, "primaryCompletionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-06-13", "studyFirstSubmitQcDate": "2008-06-16", "studyFirstPostDateStruct": {"date": "2008-06-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-11-16", "resultsFirstSubmitQcDate": "2010-11-16", "resultsFirstPostDateStruct": {"date": "2010-12-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-04-15", "lastUpdatePostDateStruct": {"date": "2011-04-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very elderly patients (greater than or equal to 70 years) with stage 1 or 2 hypertension"}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Systolic blood pressure", "Diastolic blood pressure", "Valsartan", "Hydrochlorothiazide"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 384, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan", "type": "ACTIVE_COMPARATOR", "description": "(patients initiated on valsartan)", "interventionNames": ["Drug: Valsartan"]}, {"label": "HCTZ", "type": "ACTIVE_COMPARATOR", "description": "(patients initiated on HCTZ)", "interventionNames": ["Drug: HCTZ"]}, {"label": "Valsartan + HCTZ", "type": "EXPERIMENTAL", "description": "(patients initiated on Valsartan+HCTZ)", "interventionNames": ["Drug: Valsartan + HCTZ"]}], "interventions": [{"type": "DRUG", "name": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.", "armGroupLabels": ["Valsartan + HCTZ"]}, {"type": "DRUG", "name": "Valsartan", "description": "At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.", "armGroupLabels": ["Valsartan"]}, {"type": "DRUG", "name": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.", "armGroupLabels": ["HCTZ"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 4 in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)", "timeFrame": "Baseline and Week 4"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 4, 8, 12 and 16 in Office Cuff Mean Sitting Diastolic Blood Pressure (MSDBP)", "timeFrame": "Baseline and Weeks 4, 8, 12 and 16"}, {"measure": "Change From Baseline to Weeks 8, 12 and 16 in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)", "timeFrame": "Baseline and Weeks 8, 12, and 16"}, {"measure": "Cumulative Percentage of Patients Achieving the Blood Pressure Control of < 140/90 mmHg", "description": "Cumulative refers to achieving of blood pressure control before or at the corresponding visit.", "timeFrame": "Weeks 4, 8, 12 and 16"}, {"measure": "Cumulative Percentage of Patients Achieving Blood Pressure Goal (MSSBP < 140 mmHg)", "description": "Cumulative refers to achieving blood pressure goal before or at the corresponding visit.", "timeFrame": "Weeks 4, 8, 12 and 16"}, {"measure": "Time in Weeks to Achieving the First Treatment Success (Defined as the Time of the First Achievement of the Target Blood Pressure Goal [MSSBP/MSDBP <140/90 mmHg])", "timeFrame": "During 16 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age 70 years or older.\n* Patients with hypertension prior to being randomized into study.\n* Patients must have an office cuff MSSBP \u2265 140 and \u2264 200 mmHg systolic.\n* Have the ability to communicate and comply with all study requirements.\n* Provide written informed consent to participate in the study prior to any screening or study procedures.\n\nExclusion Criteria:\n\n* Use of other investigational drugs within 30 days of enrollment.\n* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.\n* Office blood pressure measured by office machine cuff with a mean of (3) MSDBP \u2265 120 mmHg at anytime during the screening / washout period.\n* Patients taking 3 or more antihypertensive drugs and MSSBP \u2265 160 mmHg at the time of Visit 1.\n* Other protocol-defined exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "70 Years", "stdAges": ["OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Investigative site", "city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Investigative site", "city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Investigative Site", "city": "Escondido", "state": "California", "country": "United States", "geoPoint": {"lat": 33.11921, "lon": -117.08642}}, {"facility": "Investigative site", "city": "Fresno", "state": "California", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Investigative site", "city": "Huntington Park", "state": "California", "country": "United States", "geoPoint": {"lat": 33.98168, "lon": -118.22507}}, {"facility": "Investigative Sites", "city": "Pismo Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 35.14275, "lon": -120.64128}}, {"facility": "Investigative site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Investigative site", "city": "Ormond Beach", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.28581, "lon": -81.05589}}, {"facility": "Investigative site", "city": "Conyers", "state": "Georgia", "country": "United States", "geoPoint": {"lat": 33.66761, "lon": -84.01769}}, {"facility": "Investigative Site", "city": "Lexington", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Investigative site", "city": "Portland", "state": "Maine", "country": "United States", "geoPoint": {"lat": 43.66147, "lon": -70.25533}}, {"facility": "Investigative site", "city": "Las Vegas", "state": "Nevada", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Investigative site", "city": "Buffalo", "state": "New York", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Investigative site", "city": "Shelby", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.29235, "lon": -81.53565}}, {"facility": "Investigative site", "city": "Carlisle", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.582, "lon": -84.32022}}, {"facility": "Investigative site", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Investigative site", "city": "Erie", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 42.12922, "lon": -80.08506}}, {"facility": "Investigative Site", "city": "Greer", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"facility": "Investigative Site", "city": "Taylors", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 34.92039, "lon": -82.29623}}, {"facility": "Investigative site", "city": "St George", "state": "Utah", "country": "United States", "geoPoint": {"lat": 37.10415, "lon": -113.58412}}]}, "referencesModule": {"references": [{"pmid": "22520932", "type": "DERIVED", "citation": "Cushman WC, Duprez DA, Weintraub HS, Purkayastha D, Zappe D, Samuel R, Izzo JL Jr. Home and clinic blood pressure responses in elderly individuals with systolic hypertension. J Am Soc Hypertens. 2012 May-Jun;6(3):210-8. doi: 10.1016/j.jash.2012.03.001."}, {"pmid": "22311004", "type": "DERIVED", "citation": "Weintraub HS, Duprez DA, Cushman WC, Zappe DH, Purkayastha D, Samuel R, Izzo JL Jr. Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity. Cardiovasc Drugs Ther. 2012 Apr;26(2):145-55. doi: 10.1007/s10557-011-6365-x."}, {"pmid": "21974759", "type": "DERIVED", "citation": "Izzo JL Jr, Weintraub HS, Duprez DA, Purkayastha D, Zappe D, Samuel R, Cushman WC. Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results. J Clin Hypertens (Greenwich). 2011 Oct;13(10):722-30. doi: 10.1111/j.1751-7176.2011.00498.x. Epub 2011 Jul 14."}, {"pmid": "21747241", "type": "DERIVED", "citation": "Duprez DA, Weintraub HS, Cushman WC, Purkayastha D, Zappe D, Samuel R, Izzo JL Jr. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. Blood Press Monit. 2011 Aug;16(4):186-96. doi: 10.1097/MBP.0b013e32834944e9."}], "seeAlsoLinks": [{"label": "Click here for more information on the clinical study", "url": "http://www.novartisclinicaltrials.com"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan", "description": "At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"}, {"id": "FG001", "title": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."}, {"id": "FG002", "title": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "128"}, {"groupId": "FG001", "numSubjects": "128"}, {"groupId": "FG002", "numSubjects": "128"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "97"}, {"groupId": "FG002", "numSubjects": "99"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "31"}, {"groupId": "FG002", "numSubjects": "29"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Unsatisfactory Therapeutic Effect", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "7"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan", "description": "At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"}, {"id": "BG001", "title": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."}, {"id": "BG002", "title": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "128"}, {"groupId": "BG001", "value": "128"}, {"groupId": "BG002", "value": "128"}, {"groupId": "BG003", "value": "384"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "77.7", "spread": "4.22"}, {"groupId": "BG001", "value": "77.7", "spread": "4.80"}, {"groupId": "BG002", "value": "77.2", "spread": "3.99"}, {"groupId": "BG003", "value": "77.5", "spread": "4.34"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "70-75 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "44"}, {"groupId": "BG003", "value": "126"}]}]}, {"title": "76-80 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "56"}, {"groupId": "BG002", "value": "65"}, {"groupId": "BG003", "value": "181"}]}]}, {"title": ">80 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "62"}, {"groupId": "BG002", "value": "71"}, {"groupId": "BG003", "value": "214"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "66"}, {"groupId": "BG002", "value": "57"}, {"groupId": "BG003", "value": "170"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 4 in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)", "populationDescription": "Intent to treat (ITT), Last observation carried forward", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Valsartan", "description": "At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"}, {"id": "OG001", "title": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."}, {"id": "OG002", "title": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "166.2", "spread": "11.07"}, {"groupId": "OG001", "value": "164.5", "spread": "11.84"}, {"groupId": "OG002", "value": "164.5", "spread": "11.86"}]}]}, {"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "157.5", "spread": "19.71"}, {"groupId": "OG001", "value": "150.9", "spread": "18.41"}, {"groupId": "OG002", "value": "147.1", "spread": "18.35"}]}]}, {"title": "Change in MSSBP from Baseline to Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.6", "spread": "19.47"}, {"groupId": "OG001", "value": "-13.6", "spread": "16.81"}, {"groupId": "OG002", "value": "-17.3", "spread": "17.61"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 4, 8, 12 and 16 in Office Cuff Mean Sitting Diastolic Blood Pressure (MSDBP)", "populationDescription": "Intent to treat (ITT), Last observation carried forward", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Weeks 4, 8, 12 and 16", "groups": [{"id": "OG000", "title": "Valsartan", "description": "At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"}, {"id": "OG001", "title": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."}, {"id": "OG002", "title": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "84.9", "spread": "9.78"}, {"groupId": "OG001", "value": "85.5", "spread": "9.09"}, {"groupId": "OG002", "value": "84.8", "spread": "9.36"}]}]}, {"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.0", "spread": "10.61"}, {"groupId": "OG001", "value": "81.6", "spread": "10.97"}, {"groupId": "OG002", "value": "77.8", "spread": "9.66"}]}]}, {"title": "Change in MSDBP from Baseline to Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.9", "spread": "9.08"}, {"groupId": "OG001", "value": "-3.9", "spread": "10.24"}, {"groupId": "OG002", "value": "-7.1", "spread": "8.80"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.3", "spread": "10.33"}, {"groupId": "OG001", "value": "79.1", "spread": "11.97"}, {"groupId": "OG002", "value": "76.5", "spread": "9.45"}]}]}, {"title": "Change in MSDBP from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.6", "spread": "10.26"}, {"groupId": "OG001", "value": "-6.4", "spread": "10.72"}, {"groupId": "OG002", "value": "-8.4", "spread": "9.68"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.6", "spread": "11.0"}, {"groupId": "OG001", "value": "78.1", "spread": "11.42"}, {"groupId": "OG002", "value": "75.4", "spread": "8.87"}]}]}, {"title": "Change in MSDBP from Baseline to Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.3", "spread": "10.55"}, {"groupId": "OG001", "value": "-7.3", "spread": "10.75"}, {"groupId": "OG002", "value": "-9.5", "spread": "9.66"}]}]}, {"title": "Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.8", "spread": "10.34"}, {"groupId": "OG001", "value": "77.9", "spread": "11.66"}, {"groupId": "OG002", "value": "76.6", "spread": "8.42"}]}]}, {"title": "Change in MSDBP from Baseline to Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.1", "spread": "10.78"}, {"groupId": "OG001", "value": "-7.5", "spread": "10.76"}, {"groupId": "OG002", "value": "-8.3", "spread": "8.62"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Weeks 8, 12 and 16 in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)", "populationDescription": "Intent to treat (ITT), Last observation carried forward", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Weeks 8, 12, and 16", "groups": [{"id": "OG000", "title": "Valsartan", "description": "At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"}, {"id": "OG001", "title": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."}, {"id": "OG002", "title": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "166.2", "spread": "11.07"}, {"groupId": "OG001", "value": "164.5", "spread": "11.84"}, {"groupId": "OG002", "value": "164.5", "spread": "11.86"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "150.4", "spread": "20.29"}, {"groupId": "OG001", "value": "147.4", "spread": "18.69"}, {"groupId": "OG002", "value": "144.2", "spread": "19.93"}]}]}, {"title": "Change in MSSBP from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.7", "spread": "20.43"}, {"groupId": "OG001", "value": "-17.1", "spread": "17.83"}, {"groupId": "OG002", "value": "-20.2", "spread": "19.12"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "148.6", "spread": "21.45"}, {"groupId": "OG001", "value": "145.1", "spread": "19.38"}, {"groupId": "OG002", "value": "142.0", "spread": "18.78"}]}]}, {"title": "Change in MSSBP from Baseline to Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.5", "spread": "21.16"}, {"groupId": "OG001", "value": "-19.4", "spread": "19.19"}, {"groupId": "OG002", "value": "-22.5", "spread": "19.52"}]}]}, {"title": "Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "148.7", "spread": "20.06"}, {"groupId": "OG001", "value": "144.9", "spread": "19.59"}, {"groupId": "OG002", "value": "143.5", "spread": "18.69"}]}]}, {"title": "Change in MSSBP from Baseline to Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.5", "spread": "19.62"}, {"groupId": "OG001", "value": "-19.7", "spread": "19.69"}, {"groupId": "OG002", "value": "-20.9", "spread": "18.49"}]}]}]}, {"type": "SECONDARY", "title": "Cumulative Percentage of Patients Achieving the Blood Pressure Control of < 140/90 mmHg", "description": "Cumulative refers to achieving of blood pressure control before or at the corresponding visit.", "populationDescription": "Intent to treat (ITT)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Weeks 4, 8, 12 and 16", "groups": [{"id": "OG000", "title": "Valsartan", "description": "At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"}, {"id": "OG001", "title": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."}, {"id": "OG002", "title": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "37.3"}, {"groupId": "OG002", "value": "49.21"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "40.63"}, {"groupId": "OG001", "value": "50.79"}, {"groupId": "OG002", "value": "63.49"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "61.11"}, {"groupId": "OG002", "value": "69.05"}]}]}, {"title": "Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "55.47"}, {"groupId": "OG001", "value": "66.67"}, {"groupId": "OG002", "value": "72.22"}]}]}]}, {"type": "SECONDARY", "title": "Cumulative Percentage of Patients Achieving Blood Pressure Goal (MSSBP < 140 mmHg)", "description": "Cumulative refers to achieving blood pressure goal before or at the corresponding visit.", "populationDescription": "Intent to treat (ITT)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Weeks 4, 8, 12 and 16", "groups": [{"id": "OG000", "title": "Valsartan", "description": "At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"}, {"id": "OG001", "title": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."}, {"id": "OG002", "title": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "38.89"}, {"groupId": "OG002", "value": "49.21"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "40.63"}, {"groupId": "OG001", "value": "52.38"}, {"groupId": "OG002", "value": "63.49"}]}]}, {"title": "Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "62.70"}, {"groupId": "OG002", "value": "69.05"}]}]}, {"title": "Week 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.25"}, {"groupId": "OG001", "value": "68.25"}, {"groupId": "OG002", "value": "72.22"}]}]}]}, {"type": "SECONDARY", "title": "Time in Weeks to Achieving the First Treatment Success (Defined as the Time of the First Achievement of the Target Blood Pressure Goal [MSSBP/MSDBP <140/90 mmHg])", "populationDescription": "Intent to treat (ITT)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Weeks", "timeFrame": "During 16 weeks", "groups": [{"id": "OG000", "title": "Valsartan", "description": "At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"}, {"id": "OG001", "title": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."}, {"id": "OG002", "title": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.0", "lowerLimit": "8.0", "upperLimit": "12.0"}, {"groupId": "OG001", "value": "8.0", "lowerLimit": "7.0", "upperLimit": "12.0"}, {"groupId": "OG002", "value": "4.0", "lowerLimit": "3.0", "upperLimit": "8.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "16 weeks", "eventGroups": [{"id": "EG000", "title": "Valsartan + HCTZ", "description": "At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.", "seriousNumAffected": 3, "seriousNumAtRisk": 128, "otherNumAffected": 16, "otherNumAtRisk": 128}, {"id": "EG001", "title": "HCTZ", "description": "At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.", "seriousNumAffected": 4, "seriousNumAtRisk": 128, "otherNumAffected": 27, "otherNumAtRisk": 128}, {"id": "EG002", "title": "Valsartan", "description": "At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal \\<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12", "seriousNumAffected": 3, "seriousNumAtRisk": 128, "otherNumAffected": 23, "otherNumAtRisk": 128}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Gastric ulcer haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Clavicle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Spinal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Thoracic vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Lung cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 128}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 128}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 128}]}], "otherEvents": [{"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 128}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 128}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 128}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 128}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 128}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 128}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "CRC", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}